Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines

Cancer Chemotherapy and Pharmacology

Volumn 50, Issue 5, 2002, Pages 397-404

  Woessmann, Willi ^a   Chen, Xinbin ^b   Borkhardt, Arndt ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cell death; Cisplatin; Cytotoxicity; ERK; p53; Ras

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAS PROTEIN; TETRACYCLINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; NEUROBLASTOMA; NEUROBLASTOMA CELL; OSTEOSARCOMA; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; BUTADIENES; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; GENES, P53; GENES, RAS; HUMANS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM PROTEINS; NEUROBLASTOMA; NITRILES; OSTEOSARCOMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036452342     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0502-y     Document Type: Article

References (34)

1. Anthoney DA, McIlwrath AJ, Gallagher WM, Edlin AR, Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug- resistant tumor cells. Cancer Res 56:1374
2. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R (2001) Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20:147
3. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47:936
4. Chen X, Ko LJ, Jayaraman L, Prives C (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10:2438
5. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL (2000) Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 29:219
6. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95
7. DeHaan RD, Yazlovitskaya EM, Persons DL (2001) Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 48:383
8. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ (2000) Cisplatin resistance and oncogenes - A review. Anticancer Drugs 11:225
9. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 92:7686
10. Duncia JV, Santella JB, Higley CA, Pitts WJ, Wityak J, Frietze WE, Rankin FW, Sun JH, Earl RA, Tabaka AC, Teleha CA, Blom KF, Favata MF, Manos EJ, Daulerio AJ, Stradley DA, Horiuchi K, Copeland RA, Scherle PA, Trzaskos JM, Ma-golda RL, Trainor GL, Wexler RR, Hobbs FW, Olson RE (1998) MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 8:2839
11. Fanton CP, McMahon M, Pieper RO (2001) Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem 15:15
12. Gallagher WM, Cairney M, Schott B, Roninson IB, Brown R (1997) Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14:185
13. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59:9
14. 2. Role in cell survival following oxidant injury. J Biol Chem 271:4138
15. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y (1999) Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 274:31648
16. Jordan P, Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229
17. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dritschilo A, Mark GE (1989) Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science 243:1354
18. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59:1
19. Mandic A, Viktorsson K, Heiden T, Hansson J, Shoshan MC (2001) The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res 11:11
20. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55
21. Park SA, Park HJ, Lee BI, Ahn YH, Kim SU, Choi KS (2001) Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 93:18
22. Perez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34:1535
23. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC (1999) Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 5:1007
24. Persons DL, Yazlovitskaya EM, Pelling JC (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275:35778
25. Sanchez-Perez I, Murguia JR, Perona R (1998) Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533
26. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810
27. Shih A, Lin HY, Davis FB, Davis PJ (2001) Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase. Biochemistry 40:2870
28. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B, Kidd VJ, Mak TW, Ingram AJ (2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 30:30
29. Tong T, Fan W, Zhao H, Jin S, Fan F, Blanck P, Alomo I, Rajasekaran B, Liu Y, Holbrook NJ, Zhan Q (2001) Involvement of the MAP kinase pathways in induction of GADD45 following UV radiation. Exp Cell Res 269:64
30. Wang X, Martindale JL, Holbrook NJ (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 275:39435
31. Woessmann W, Meng YH, Mivechi NF (1999) An essential role for mitogen-activated protein kinases, ERKs, in preventing heat-induced cell death. J Cell Biochem 74:648
32. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M (1997) Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17:5598
33. Yazlovitskaya EM, DeHaan RD, Persons DL (2001) Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 283:732
34. Zamble DB, Jacks T, Lippard SJ (1998) p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci U S A 95:6163